ST Jude Children's Research Hospital Inc.

ST Jude Children's Research Hospital Inc., headquartered in Memphis, Tennessee, is a tax-exempt non-profit hospital and pediatric cancer research institution that receives federal grant funding as a prime recipient across the National Institutes of Health and Department of Defense. The organization does not hold federal contracts or operate as a subcontractor to other federal primes; it participates in the federal grants ecosystem exclusively as a direct recipient and, in sub-grant arrangements, as a sub-recipient under other NIH-funded prime grantees. ST Jude operates across 42 distinct federal customer agencies, with overwhelming concentration in the NIH — the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Heart, Lung, and Blood Institute together account for 66 percent of recent award count and 54 percent of combined potential value across the portfolio.

ST Jude's federal research mission centers on pediatric oncology, immunology, infectious disease, and translational biomedical science. Recent prime grant awards span investigator-initiated Project Grants funding basic and applied research in cancer biology, immunotherapy development, drug resistance mechanisms, gene editing and CRISPR technologies, vaccine development, hematologic disease, and neurological disorders. Representative work includes a $3.03 billion Program Project Grant from the National Cancer Institute (award date September 1, 2025; completion August 31, 2030) investigating fusion oncoprotein-driven pediatric cancers through biomolecular condensate formation and epigenetic mechanisms; a $1.94 million cooperative agreement from the Department of Agriculture Animal and Plant Health Inspection Service (award date February 2, 2026; completion January 31, 2029) on high-pathogenicity avian influenza transmission to commercial poultry with subawards to the University of Minnesota and Penn State University; and multiple Defense Health Agency project grants (September 1, 2025 through September 1, 2024 awards totaling approximately $4.9 million) targeting pediatric kidney cancer, liver cancer, Langerhans cell histiocytosis, and bone marrow failure mechanisms. The National Institute of Allergy and Infectious Diseases funded a $3.43 million project grant (July 22, 2025; June 30, 2029) on epigenetic checkpoint regulation of naive T-cell quiescence and peripheral tolerance, and the National Heart, Lung, and Blood Institute obligated $835 thousand (June 15, 2026; February 28, 2030) on fatty acid metabolism in erythropoiesis with therapeutic implications for hemoglobinopathies.

The portfolio shows consistent activity across five fiscal years, with 990 total federal awards (729 prime, 261 sub) and combined potential value of $878.6 million against combined obligated dollars of $2.93 billion—reflecting substantial draw-downs on multi-year grants. Award volume per year ranged from 60 (FY2023) to 113 (FY2024), with 95 awards facing ultimate completion in the next 24 months, creating significant recompete exposure. Service Contract Inventory data covering FY2022–FY2025 shows SCI-reported invoiced revenue of $81.2 million on prime records, with FY2025 reaching $22.4 million across 83.2 FTEs. Government-paid hourly rates span a median of $191.82/hr (10th percentile $104.62/hr; 90th percentile $471.45/hr), reflecting mixed labor grades from clinical research coordinators to senior scientists. Across prime SCI records, subcontractors performed 27 percent of total contractor hours on average, drawing on a sub base of 109 named subcontractors, with notable sub-recipients including University of Minnesota, Penn State University, University of Florida, University of Georgia Research Foundation, Children's Hospital of Philadelphia, and Mayo Clinic, typically positioned for specialized research execution rather than prime delivery.

ST Jude operates as a direct NIH grant recipient—not as a federal contractor or systems integrator—and competes in full-and-open federal research opportunities without set-aside posture. The institution's federal footprint is research funding, not procurement of services, goods, or IT systems for federal agencies.